BRAF and thyroid gland carcinoma: The T1799A point BRAF mutation (a V600E amino acid change in the BRAF protein resulting in constitutive and oncogenic activation of the BRAF kinase) represents more than 90% of all BRAF mutations in human cancer and is the most common genetic alteration in thyroid cancer (a somatic rather than germline mutation in thyroid cancer) [9].